Potera M E, Lookingbill D P, Stryker J A
Radiology. 1982 Jun;143(3):775-7. doi: 10.1148/radiology.143.3.7079509.
Nineteen cancer patients receiving radiation therapy to the head, neck, chest wall, or abdomen were evaluated in a double-blind study to determine the effectiveness of 0.2% hydrocortisone valerate vs. placebo in reducing acute radiation dermatitis. Patients applied hydrocortisone valerate to one-half of the irradiate area and the placebo to the other half beginning two weeks after the initiation of radiotherapy and continuing until three weeks after completion. Left and right sides were scored each week with respect to erythema, dry desquamation, moist desquamation, ulceration, and the duration and intensity of symptoms such as soreness, burning, and itching. No statistically significant difference was found between the 0.2% hydrocortisone valerate and the placebo in the acute skin response or the symptoms of radiation dermatitis. The patients were evaluated three months following radiotherapy for evidence of skin atrophy. There were no differences found between hydrocortisone valerate and the placebo with respect to the late effects of radiation therapy.
在一项双盲研究中，对19名接受头部、颈部、胸壁或腹部放射治疗的癌症患者进行了评估，以确定0.2%戊酸氢化可的松与安慰剂相比在减轻急性放射性皮炎方面的有效性。从放疗开始两周后，患者将戊酸氢化可的松涂抹在照射区域的一半，将安慰剂涂抹在另一半，持续至放疗结束后三周。每周对左右两侧的红斑、干性脱屑、湿性脱屑、溃疡以及疼痛、灼痛和瘙痒等症状的持续时间和强度进行评分。在急性皮肤反应或放射性皮炎症状方面，0.2%戊酸氢化可的松与安慰剂之间未发现统计学上的显著差异。放疗三个月后对患者进行评估，以检查皮肤萎缩的迹象。在放疗的晚期效应方面，戊酸氢化可的松与安慰剂之间未发现差异。
